HCW Biologics Announces Reverse Stock Split Implementation
HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company based in Miramar, is advancing its mission to combat age-related diseases through innovative immunotherapies. In an important move, the Company has disclosed a 1-for-40 reverse stock split that aims to reposition its stock for better market compliance. This strategic action is slated to take effect on a set date, allowing stock adjustments that reflect a more favorable trading value.
Details of the Reverse Stock Split
Understanding the Split
The reverse stock split will convert 40 ordinary shares into just one share, which will help HCW Biologics align itself with Nasdaq listing requirements, specifically the minimum bid price threshold of $1.00 per share. Following this split, the Company will see a significant reduction in its issued shares from approximately 44.9 million to about 1.1 million shares. Nevertheless, the total authorized shares will remain unchanged at 250 million, ensuring the Company's capacity for future growth remains intact.
Impact on Stockholders
This adjustment will not affect the percentage ownership of existing shareholders, aside from those who end up with fractional shares. Interestingly, instead of receiving partial shares, stockholders entitled to fractions will automatically receive one full share. This approach ensures that all shareholders maintain participation in the Company’s progress.
Strategic Decision Towards Compliance
The driving force behind this reverse stock split is to enhance the company’s market presence and conform to Nasdaq’s stringent listing regulations. Compliance with these requirements is essential for HCW Biologics to secure its standing in the market and to foster investor confidence.
Equity Management Adjustments
Adjustments Following the Split
Post-split, the adjustments will extend to the stock options and warrants as well. The exercise prices will be modified according to the terms stipulated, ensuring that all equity-related aspects of the Company align with the new share structure. HCW Biologics has engaged Equiniti Trust Company LLC to facilitate these changes smoothly for all stockholders.
Who Needs to Take Action?
For most stockholders holding shares in electronic form, there’s no action required as the shares will automatically reflect the changes via Equiniti. However, those with shares held in street name are advised to follow instructions from their respective brokers to understand how their holdings will be affected.
About HCW Biologics Inc.
HCW Biologics is dedicated to the research and development of pioneering immunotherapies targeting chronic inflammation and age-related ailments, including cancer and autoimmune disorders. The Company is utilizing advanced protein engineering to spearhead two unique drug discovery platforms. These innovative programs are expected to elevate the therapeutic landscape and offer widespread treatment avenues for various diseases.
Frequently Asked Questions
What is a reverse stock split?
A reverse stock split is when a company reduces the number of its outstanding shares to increase the share price proportionally.
Why did HCW Biologics implement a reverse stock split?
The reverse stock split was executed to meet Nasdaq's minimum bid price requirement to maintain its listing.
How will the reverse stock split affect my shares?
Shareholders will see their total number of shares decrease, but their overall ownership percentage remains unchanged, aside from fractional shares which will be rounded up.
When will the reverse stock split take effect?
The reverse stock split is set to take effect at 12:01 a.m. Eastern Time on a specified date.
Who is the transfer agent handling this process?
Equiniti Trust Company LLC is acting as the exchange agent for the reverse stock split.
